- Issuer ticker
-
BDX
- Reported as of
-
17 Dec 2025
- Net transaction value
-
-$123,303
- SEC form
-
4
- Accepted by SEC
-
17 Dec 2025, 20:12:57 UTC
Filing notes and source
Key filing fact
Michael David Garrison filed Form 4 for BECTON DICKINSON & CO (BDX) on 17 Dec 2025.
Key facts
- This page summarizes Michael David Garrison's Form 4 filing for BECTON DICKINSON & CO (BDX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2025, 20:12.
Change
- Previous filing in this sequence was filed on 01 Dec 2025.
- Current net transaction value: -$123,303.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001944816
Primary reporting owner
Garrison Michael David
- Relationship
-
EVP & Pres Med.Essntl&BioPharm
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BDX
transaction
Common Stock
Sale
- Transaction value
- -$123,303
- Shares
- -629
- Change %
- -4.6%
- Price
-
$196.03
- Shares after
- 13,105
- Date
- 17 Dec 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
SEC remarks
The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2025.